F
Fen Yu
Researcher at University of Michigan
Publications - 8
Citations - 180
Fen Yu is an academic researcher from University of Michigan. The author has contributed to research in topics: Anthrax vaccines & Bacillus anthracis. The author has an hindex of 7, co-authored 8 publications receiving 174 citations.
Papers
More filters
Journal ArticleDOI
A Synthetic Peptide Vaccine Directed against the 2β2–2β3 Loop of Domain 2 of Protective Antigen Protects Rabbits from Inhalation Anthrax
TL;DR: It is concluded that a synthetic peptide vaccine targeting the LND would be a potentially efficacious vaccine for anthrax.
Journal ArticleDOI
Synthetic Peptide Vaccine Targeting a Cryptic Neutralizing Epitope in Domain 2 of Bacillus anthracis Protective Antigen
Jon Oscherwitz,Jon Oscherwitz,Fen Yu,Jana L. Jacobs,Te Hui Liu,Philip R. Johnson,Kemp B. Cease,Kemp B. Cease +7 more
TL;DR: Analysis of sera from multiple cohorts of rabbits with high-titer immunity to PA demonstrated a virtual absence of this potent antibody specificity, and work by others suggests that this specificity may be present at only low levels in primate PA antiserum.
Journal ArticleDOI
Low-dose intraperitoneal Freund's adjuvant: Toxicity and immunogenicity in mice using an immunogen targeting amyloid-β peptide
TL;DR: Though a high-titered, humoral response may be generated using low dose CFA administered i.p. to mice, the accompanying toxicity remains significant, and thus alternative adjuvants and/or routes should be considered.
Journal ArticleDOI
A Heterologous Helper T-Cell Epitope Enhances the Immunogenicity of a Multiple-Antigenic-Peptide Vaccine Targeting the Cryptic Loop-Neutralizing Determinant of Bacillus anthracis Protective Antigen
TL;DR: Immunization with MAPs containing the P30 epitope elicited higher antibody and toxin neutralization titers and peptide-specific affinity than immunization with an LND MAP lacking a helper epitope, and P30-containing MAP304 represents a promising LND-specific vaccine for anthrax.
Journal ArticleDOI
Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.
Te Hui Liu,Jon Oscherwitz,Bruce C. Schnepp,Jana L. Jacobs,Fen Yu,Kemp B. Cease,Kemp B. Cease,Philip R. Johnson +7 more
TL;DR: The finding of robust neutralizing antibody responses after a single injection of these rAAV1-based vectors supports their further development as candidate anthrax vaccines.